Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
$1.35
-3.6%
$1.25
$0.86
$3.36
$84.80M0.14584,109 shs89,035 shs
CryoPort, Inc. stock logo
CYRX
CryoPort
$7.27
-0.8%
$7.03
$4.58
$9.66
$367.51M1.88408,366 shs485,962 shs
Humacyte, Inc. stock logo
HUMA
Humacyte
$2.28
-5.0%
$2.42
$1.15
$8.72
$372.29M1.94.15 million shs5.79 million shs
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$21.60
-1.5%
$17.61
$10.80
$25.29
$317.31M0.22145,336 shs58,806 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
-3.57%-14.01%+19.47%+25.00%-59.09%
CryoPort, Inc. stock logo
CYRX
CryoPort
-0.82%-7.39%-2.28%+24.06%-21.24%
Humacyte, Inc. stock logo
HUMA
Humacyte
-5.00%-9.88%-1.30%+74.05%-75.90%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-1.46%-6.41%+37.23%+77.78%+48.86%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
2.5697 of 5 stars
3.55.00.00.00.01.70.6
CryoPort, Inc. stock logo
CYRX
CryoPort
2.1548 of 5 stars
3.42.00.00.01.12.50.6
Humacyte, Inc. stock logo
HUMA
Humacyte
1.7073 of 5 stars
3.51.00.00.01.80.80.6
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
1.3548 of 5 stars
0.01.00.04.60.62.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
3.00
Buy$6.33369.14% Upside
CryoPort, Inc. stock logo
CYRX
CryoPort
2.75
Moderate Buy$10.6346.15% Upside
Humacyte, Inc. stock logo
HUMA
Humacyte
3.00
Buy$11.71413.78% Upside
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest ABOS, HUMA, CYRX, and INBX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/23/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
7/22/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$13.00
7/9/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
7/7/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$13.00 ➝ $10.00
6/17/2025
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$4.00
6/9/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
5/15/2025
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
5/14/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$4.00
5/14/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$17.00 ➝ $14.00
5/13/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
5/8/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
N/AN/AN/AN/A$3.03 per shareN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
$228.38M1.60N/AN/A$7.44 per share0.98
Humacyte, Inc. stock logo
HUMA
Humacyte
$1.57M225.27N/AN/A($0.41) per share-5.56
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$200K1,563.84$113.68 per share0.19$9.23 per share2.34
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
-$102.33M-$1.94N/AN/AN/AN/A-58.24%-46.53%8/12/2025 (Estimated)
CryoPort, Inc. stock logo
CYRX
CryoPort
-$114.76M-$2.34N/AN/AN/A-50.15%-11.03%-5.54%8/5/2025 (Estimated)
Humacyte, Inc. stock logo
HUMA
Humacyte
-$148.70M-$0.69N/AN/AN/AN/AN/A-73.59%8/12/2025 (Estimated)
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$1.69B$116.750.19N/AN/AN/A-85.12%-58.90%8/12/2025 (Estimated)

Latest ABOS, HUMA, CYRX, and INBX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
-$0.54N/AN/AN/AN/AN/A
8/12/2025Q2 2025
Humacyte, Inc. stock logo
HUMA
Humacyte
-$0.15N/AN/AN/A$0.94 millionN/A
8/12/2025Q2 2025
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$2.92N/AN/AN/AN/AN/A
8/5/2025Q2 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.20N/AN/AN/A$41.74 millionN/A
5/14/2025Q4 2024
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$2.55-$2.80-$0.25-$2.80N/AN/A
5/13/2025Q1 2025
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
-$0.56-$0.48+$0.08-$0.48N/AN/A
5/13/2025Q1 2025
Humacyte, Inc. stock logo
HUMA
Humacyte
-$0.19-$0.10+$0.09$0.28$0.46 million$0.52 million
5/7/2025Q1 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.23-$0.22+$0.01-$0.28$56.19 million$41.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
N/AN/AN/AN/AN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
Humacyte, Inc. stock logo
HUMA
Humacyte
N/AN/AN/AN/AN/A
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
0.19
8.02
8.02
CryoPort, Inc. stock logo
CYRX
CryoPort
0.51
5.56
5.24
Humacyte, Inc. stock logo
HUMA
Humacyte
0.36
3.68
3.28
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
1.04
5.12
5.12

Institutional Ownership

CompanyInstitutional Ownership
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
71.01%
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
Humacyte, Inc. stock logo
HUMA
Humacyte
44.71%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
82.46%

Insider Ownership

CompanyInsider Ownership
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
9.30%
CryoPort, Inc. stock logo
CYRX
CryoPort
10.00%
Humacyte, Inc. stock logo
HUMA
Humacyte
5.10%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
17.09%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
2060.57 million54.94 millionOptionable
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.14 million45.12 millionOptionable
Humacyte, Inc. stock logo
HUMA
Humacyte
150155.12 million147.21 millionOptionable
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
16614.48 million12.00 millionOptionable

Recent News About These Companies

Inhibrx Biosciences, Inc. (INBX) - Yahoo Finance
Inhibrx Biosciences Inc (INBX) - Investing.com
Inhibrx announces leadership changes as co-founder departs
When the Price of (INBX) Talks, People Listen
Inhibrx Biosciences Inc (INBX) Gets a Hold from JMP Securities

New MarketBeat Followers Over Time

Media Sentiment Over Time

Acumen Pharmaceuticals stock logo

Acumen Pharmaceuticals NASDAQ:ABOS

$1.35 -0.05 (-3.57%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.35 0.00 (0.00%)
As of 08/1/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

CryoPort stock logo

CryoPort NASDAQ:CYRX

$7.27 -0.06 (-0.82%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$7.27 0.00 (0.00%)
As of 08/1/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Humacyte stock logo

Humacyte NASDAQ:HUMA

$2.28 -0.12 (-5.00%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$2.26 -0.02 (-0.83%)
As of 08/1/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Inhibrx Biosciences stock logo

Inhibrx Biosciences NASDAQ:INBX

$21.60 -0.32 (-1.46%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$21.64 +0.04 (+0.19%)
As of 08/1/2025 04:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.